Company Data
Kiniksa Pharmaceuticals Ltd.
Ticker
KNSA
Current Price
$44.9 -0.93%
Market Cap
$3.5B
Price Target
Refer to Report
Volume
1.0M
52wk Range
$19.62 - $50.03
Overview
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.